Dr. Falk Pharma and Renexxion Announce Naronapride Phase 2b Gastroparesis Results at DDW 2026

Key Takeaways

• Global Phase 2b MOVE-IT study of naronapride in 328 adults with moderate-to-severe gastroparesis selected for late-breaking presentation at DDW 2026
• Study targets both idiopathic and diabetic gastroparesis patients, addressing significant unmet medical need in digestive disorders
• Late-breaker designation indicates potentially significant clinical results that could advance gastroparesis treatment options

---

Dr. Falk Pharma and Renexxion Announce Major Gastroparesis Study Results

FREIBURG, Germany and ROSCREA, Ireland – Dr. Falk Pharma GmbH and Renexxion Ireland Limited announced April 16, 2026, that their Global Phase 2b MOVE-IT study results for naronapride have been selected for a late-breaking oral presentation at Digestive Disease Week (DDW) 2026.

Study Details and Patient Population

The MOVE-IT study evaluated naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis. Gastroparesis is a chronic digestive disorder characterized by delayed gastric emptying, affecting millions worldwide with limited treatment options.

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, partnered with clinical-stage biopharmaceutical company Renexxion to develop this potential breakthrough treatment.

Market Impact and Clinical Significance

The late-breaker designation at DDW 2026 suggests the study results may represent significant clinical advancement. Gastroparesis patients currently face limited therapeutic options, making naronapride’s development particularly important for the gastroenterology community.

Digestive Disease Week represents the premier forum for gastroenterology research, where late-breaking presentations typically showcase the most impactful clinical findings. The selection indicates potential regulatory and commercial significance for both companies.

Next Steps and Timeline

The oral presentation at DDW 2026 will provide detailed efficacy and safety data from the Phase 2b trial. These results will likely inform future Phase 3 development plans and potential regulatory submissions for naronapride in gastroparesis treatment.

Both companies are positioned to advance naronapride through later-stage development based on the study outcomes, potentially bringing new hope to gastroparesis patients who have few effective treatment alternatives.

---

Frequently Asked Questions

What is gastroparesis and how does naronapride help?

Gastroparesis is a digestive disorder causing delayed stomach emptying. Naronapride is being studied as a potential treatment to improve gastric motility in patients with moderate-to-severe idiopathic or diabetic gastroparesis.

When will naronapride be available to patients?

Naronapride is currently in Phase 2b trials. If results are positive, the companies will likely proceed to Phase 3 studies before seeking regulatory approval, which typically takes several more years.

What makes this study significant for gastroparesis treatment?

The MOVE-IT study’s selection as a late-breaker at DDW 2026 suggests potentially significant results. Gastroparesis patients have limited treatment options, making any effective new therapy clinically important.

Related coverage

• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
• Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst